This fast track antibody is not yet fully characterized. It is subject to these terms and conditions

Anti-FANCG (phospho S383) antibody (ab31893)

Overview

Properties

  • FormLiquid
  • Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: 1% BSA, PBS, pH 7.4
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Clonality Polyclonal
  • IsotypeIgG
  • Research Areas

Applications

  • Application notesThis antibody gave a positive result in ELISA against the immunizing peptide (ab33127). It gave a negative result in ELISA against the non-modified equivalent peptide (ab42660). This indicates that it is specific for the modified peptide.
    See figure below.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionDNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Candidate tumor suppressor gene.
    • Tissue specificityHighly expressed in testis and thymus. Found in lymphoblasts.
    • Involvement in diseaseDefects in FANCG are a cause of Fanconi anemia (FA) [MIM:227650]. FA is a genetically heterogeneous, autosomal recessive disorder characterized by progressive pancytopenia, a diverse assortment of congenital malformations, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage), and defective DNA repair.
    • Sequence similaritiesContains 4 TPR repeats.
    • Cellular localizationNucleus. Cytoplasm. The major form is nuclear. The minor form is cytoplasmic.
    • Information by UniProt
    • Database links
    • Alternative names
      • DNA repair protein XRCC9 antibody
      • DNA-repair protein XRCC9 antibody
      • FAG antibody
      • FANCG antibody
      • FANCG_HUMAN antibody
      • Fanconi anaemia complementation group G antibody
      • Fanconi anemia group G protein antibody
      • Protein FACG antibody
      • X ray repair, complementing defective, in Chinese hamster cells 9 antibody
      • X-ray repair, complementing defective, in Chinese hamster, 9 antibody
      • XRCC9 antibody
      see all

    Anti-FANCG (phospho S383) antibody images

    This Fast-Track antibody is not yet fully characterised. These images represent inconclusive preliminary data.

    • This antibody gave a positive result in ELISA against the immunizing peptide (ab33127, blue). It gave a negative result in ELISA against the non-modified equivalent peptide (ab42660, purple). This indicates that it is specific for the modified peptide.
          

    • CC/IF image of ab31893 stained human HepG2 cells. The cells were 4% PFA fixed (10 min), permabilised in 0.1% PBS-Tween (20 min) and incubated with the antibody (ab31893, 5µg/ml) for 1h at room temperature. 1%BSA / 10% normal goat serum / 0.3M glycine was used to block non-specific protein-protein interactions. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red). DAPI was used to stain the cell nuclei (blue). This antibody also gave a positive IF result in HeLa, HEK 293 and MCF7 cells.  However, this Fast-Track antibody is not yet fully characterised.  This image represents inconclusive preliminary data.

    References for Anti-FANCG (phospho S383) antibody (ab31893)

    ab31893 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab31893.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"